

skills to enhance their relationships, and support dealing with other life or family challenges they might experience. Up to five Fatherhood Family—focused, Interconnected, Resilient, and Essential (Fatherhood FIRE) grant recipients will partner with the Fatherhood TIES study team to participate in an implementation and impact study. The implementation study will examine how the core components are implemented and what fathers think of them. The impact study

will rigorously evaluate whether promising core components bring about positive outcomes for fathers and their families which may include understanding effects of program engagement, employment and earnings, father-child relationship quality and co-parenting relationship quality. This notice is specific to data collection activities needed to collect consent of participants to enter the study, collect additional baseline information beyond what they already provide (Healthy

Marriage and Responsible Fatherhood Performance Measures and Additional Data Collection; OMB #: 0970–0566), and collect some implementation study data. A future notice will provide information about additional data collection activities for the impact and implementation studies.

Respondents: Fathers enrolled in the Fatherhood TIES study, and program staff involved in supporting and implementing the Fatherhood TIES study.

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents (total over request period)	Number of responses per respondent (total over request period)	Avg. burden per response (in hours)	Total burden (in hours)	Annual burden (in hours)
Consent for those over 18 years old (staff)	20	188	.167	628	314
Additional Baseline Data Collection	3,000	1	.33	990	495
Program Information and Management Tool (TIES Table)	20	80	.083	133	67
Observation Form	25	12	.75	225	113
Reflection (staff)	37	17	.25	157	79
Reflection (participant)	3,000	1	.25	750	375
Estimated Annual Burden Total	1,443

Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Authority: Section 413 of the Social Security Act, as amended by the FY 2017 Consolidated Appropriations Act, 2017 (Pub. L. 115–31).

Mary B. Jones,

ACF/OPRE Certifying Officer.

[FR Doc. 2023–15694 Filed 7–24–23; 8:45 am]

BILLING CODE 4184–73–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Administration for Children and Families

[CFDA Number: 93.604]

Announcement of the Intent To Award Nine Supplements to ORR Grant Recipients in Seven States

AGENCY: Office of Refugee Resettlement (ORR), Administration for Children and Families (ACF), U.S. Department of Health and Human Services (HHS).

ACTION: Notice of issuance of supplements.

SUMMARY: ACF, ORR, Division of Refugee Health (DRH) announces the intent to award supplements in the aggregate amount of up to \$466,563 to nine grant recipients under Notice of Funding Opportunity: Direct Services for Survivors of Torture, HHS–2022–ACF–ORR–ZT–0051. The purpose of the awards is to ensure that the 222 Nicaraguan Humanitarian Parolees (NHP) who were brought to the United

States will have access to holistic care and services. This supplement will enable the identified grant recipients in California, Florida, Georgia, Maryland, Minnesota, Texas, and Virginia to provide access to medical, mental health, social, and legal services to NHP within their geographic service areas, and coordinate with The Center for Victims of Torture in Minnesota and other providers to serve NHP outside their service areas. The goal of these services is to help the NHP improve their health, find employment and stable housing, and regularize their immigration status.

DATES: The proposed period of performance is 9/30/2022 to 9/29/2023.

FOR FURTHER INFORMATION CONTACT: Margaret Brewinski-Isaacs, DRH Director, Office of Refugee Resettlement, 330 C Street Address SW, Washington, DC 20201. Telephone: (202) 401–7237; Email: Margaret.Brewinskiisaacs@acf.hhs.gov.

SUPPLEMENTARY INFORMATION: ORR announces the intent to award the following supplement awards:

Recipient	Award amount
Gulf Coast Jewish Family and Community Services, Clearwater, Florida	\$136,563
HIAS, Capital Area Healing Coalition, Silver Spring, Maryland	52,500
Asylee Women Enterprise, Inc., Baltimore, Maryland	30,000
Northern Virginia Family Service, Oakton, Virginia	62,500
Center for Survivors of Torture, Austin, Texas	30,000

Recipient	Award amount
Partnership for Trauma Recovery, Berkeley, California	30,000
Program for Torture Victims LA County, Los Angeles, California	20,000
The Center for Victims of Torture, Atlanta, Georgia	\$3,000
The Center for Victims of Torture, St. Paul, Minnesota	70,000

These programs will provide direct services to the 222 Nicaraguan Humanitarian Parolees (NHP) who were released from prison in Nicaragua and brought to the United States by the U.S. Department of State in February 2023.

On February 16, 2023, ORR issued Dear Colleague Letter 23-16, which stated that while the NHP's current immigration status does not provide eligibility for refugee program assistance, they may apply for assistance from ORR-funded Survivors of Torture (SOT) grant recipients. ORR has been working closely with the U.S. Department of State to connect these individuals to SOT grant recipients and other local service providers. Due to the nature and length of the NHP's detention in Nicaragua, their sudden release from prison and entry into the United States, and their temporary immigration status, these individuals need immediate assistance. The SOT grant recipients identified above are willing to provide medical, mental health, case management, and legal services to these individuals. However, the timing of these arrivals and the concentration in certain states has overwhelmed the capacity of SOT grant recipients in these locations. The supplemental awards will enhance the grant recipients' capacity to provide essential care and support for NHP so that they can begin the healing process.

Statutory Authority: Section 5(a) of the "Torture Victims Relief Act of 1998," Public Law 105-320 (22 U.S.C. 2152 note) Assistance for Treatment of Torture Victims.

Karen D. Shields,

Senior Grants Policy Specialist, Office of Grants Policy, Office of Administration.

[FR Doc. 2023-15650 Filed 7-24-23; 8:45 am]

BILLING CODE 4184-46-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-N-0155]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Quantitative Research on Front of Package Labeling on Packaged Foods; Reopening of the Comment Period

AGENCY: Food and Drug Administration, Department of Health and Human Services (HHS).

ACTION: Notice; reopening of the comment period.

SUMMARY: The Food and Drug Administration (FDA or we) is reopening the comment period for the notice entitled "Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Quantitative Research on Front of Package Labeling on Packaged Foods," published in the **Federal Register** of June 15, 2023, to allow interested parties additional time to submit comments. We are taking this action due to technical difficulties experienced on the final two days of the comment period that may have prevented some interested parties from submitting comments.

DATES: FDA is reopening the comment period on the notice published on June 15, 2023 (88 FR 39257). Submit written comments (including recommendations) on the collection of information by 11:59 p.m. on Wednesday, July 26, 2023.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to https://www.reginfo.gov/public/do/PRA/icrPublicCommentRequest?ref_nbr=202306-0910-004. You may also find this particular information collection at <https://www.reginfo.gov/public/do/PRAMain> by following these instructions: Under the header "Currently under Review Select Agency" use the drop down menu to select "Department of Health and Human Services" or by using the search function. The title of this information

collection is "Quantitative Research on Front of Package Labeling on Packaged Foods." Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT:

JonnaLynn Capezzuto, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-3794, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of June 15, 2023 (88 FR 39257), FDA announced that a proposed collection of information had been submitted to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995. Interested parties were originally given until July 17, 2023, to submit comments (including recommendations) on the information collection.

However, on July 16 and 17, 2023, technical difficulties may have prevented some stakeholders from submitting electronic comments. Therefore, we are reopening the comment period to allow interested parties additional time to submit comments. The reopened comment period provides an opportunity for stakeholders who may have been impacted by the technical difficulties.

Dated: July 19, 2023.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2023-15639 Filed 7-24-23; 8:45 am]

BILLING CODE 4164-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA-2022-D-0055 and FDA-2020-N-1790]

M7(R2) Assessment and Control of Deoxyribonucleic Acid Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk, M7(R2) Addendum, and M7(R2) Questions and Answers; International Council for Harmonisation; Guidances for Industry; Availability

AGENCY: Food and Drug Administration, HHS.